-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Just look at the K-line chart of Jiu'an Medical to know how much our medical and medical sector needs a dose of chicken blood
.
As the most concerned "New Year's Eve monster" in the A-share market, Jiu'an Medical has pulled out 26 daily limits in 48 trading days with an admission ticket to the new crown detection reagents in the US market.
An increase of nearly 30 billion yuan
.
During this period, the company issued warnings of abnormal fluctuations in stock trading many times, and the Shenzhen Stock Exchange even sent letters of concern, but it still failed to curb the "high fever" momentum of its stock price
.
Such a surge is far from being explained by any fundamentals
How was the "Demon King" made?
01.
"Barbarian" dimensionality reduction strike
"Barbarian" dimensionality reduction strike
At the end of 2021, Jiu'an Medical is undoubtedly the most beautiful in the field of IVD (in vitro diagnosis)
.
Just when the market was asserting that its good fortune would never last for the New Year, it came back from a New Year's Day holiday and it rose even more
In this way, a new story of "reagents going overseas" opened up the imagination of a tens of billions market, greatly stimulated the nerves of investors, and made Jiu'an Medical start a crazy journey of daily limit
02.
Those who get the certificate will get the world
03.
List of changes in the number of shareholders of Jiu'an Medical (blue curve) Data source: Oriental Fortune.
com The birth of Jiu'an Medical once again proves that "demon stocks" generally only appear at the most vulnerable moments of the market
.
Looking back on the whole of 2021, A-share and H-share listed medical and health companies have lost about 1.
This is a moment when "demon stocks need the market, and the market also needs demon stocks"
.
It is worth vigilant that, whether it is Jiu'an Medical or the entire new crown testing sector, the current capital flow shows that the net inflow of small orders is intensive, while the large orders are withdrawing rapidly.
possible
.
That is, once the wind of the new crown stops, where else can companies open up new markets large enough to undertake their own tenfold expansion of production capacity?